Dare BioscienceDARE -3.85%23 Net Margin % is -1,973.68% as of Mar. 2026. GuruFocus rates DARE with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, Dare Bioscience ranks worse than 79.18% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Dare Bioscience's Net Income for the
three
months ended in Mar. 2026 was $-3.00 Mil. Dare Bioscience's Revenue for the
three
months ended in Mar. 2026 was $0.15 Mil. Therefore, Dare Bioscience's net margin for the quarter that ended in Mar. 2026 was -1,973.68%.
The historical rank and industry rank for Dare Bioscience's Net Margin % or its related term are showing as below:
DARE'
s Net Margin % Range Over the Past 10 Years
Min: -40540 Med: -1187.49 Max: -309.48
Current: -1038.98
DARE's Net Margin % is ranked worse than 79.18% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs DARE: -1038.98
Dare Bioscience (NAS:DARE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Dare Bioscience Net Margin % Related Terms
Dare Bioscience Net Margin % Historical Data
* Premium members only.
The historical data trend for Dare Bioscience's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dare Bioscience's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dare Bioscience Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dare Bioscience's Net Margin % distribution charts can be found below:
* The bar in red indicates where Dare Bioscience's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (DARE) has a Net Margin % of -1,973.68% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Dare Bioscience and its competitors. According to the industry distribution chart, Dare Bioscience ranks #749 out of 946 companies in the Biotechnology industry, placing it in the top 79.2%.
Is Dare Bioscience's Net Margin % too high?
Dare Bioscience's current Net Margin % is -1,973.68%. Based on the distribution chart, Dare Bioscience ranks #749 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dare Bioscience has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's Net Margin % compare to TVGN and LITS?
According to the Biotechnology industry distribution chart, Dare Bioscience ranks #749 out of 946 companies for Net Margin %. This places Dare Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Dare Bioscience and its competitors. Dare Bioscience's current Net Margin % is -1,973.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current Net Margin % of -1,973.68%. The current Net Margin % is -1,973.68%. Dare Bioscience's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Dare Bioscience (DARE), the current Net Margin % is -1,973.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
23GF Score
Get the complete analysis for DARE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DARE has been successfully added to your 
